ClinicalTrials.gg
RecruitingNCT06220448BADGUYUpdated Nov 12, 2026

Blunt ADrenal Gland injUrY (BAD GUY) Project

An observational study in Trauma and Adrenal Gland Injury, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 16 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Niguarda Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
16 Years to 99 Years
Sex
All
01

Study summary

Type: retrospective observational multicenter trial. Population of interest: adult patients suffering from thoraco-abdominal trauma undergoing both non-operative and operative management.

Hypothesis: Adrenal gland injury is a rare finding after blunt thoracoabdominal trauma. Short-term outcomes of blunt adrenal gland injury (BAGI) described in literature are contradictory. Reports on the outcomes related to this injury are variable and consider heterogeneous populations of trauma patients Aim: This study aims to explore the burden related to BAGI in an homogeneous population of patients sustaining blunt thoraco-abdominal trauma treated in different institution

Read the detailed description

Adrenal gland injury is a rare finding after blunt thoracoabdominal trauma. The diagnosis can be accurately made with CT scan in stable patients, whilst in unstable patients, the detection can often be made during surgery, in the post-operative setting or postmortem. Short-term outcomes of blunt adrenal gland injury (BAGI) described in literature are contradictory. Studies reported BAGI as a high mortality risk injury. On the other hand, according to further reports, the presence of a BAGI is not considered a marker of severe injury or associated with an increased mortality rate.

Evidences the from a large multicenter cohort of selected trauma patients are lacking.

The study hypothesis is that BAGI is related to patients with higher trauma severity and worse overall outcome. By exploring the clinical burden related to BAGI the investigators aim to determine if this is related to the anatomical location of the injured organ or if in addition an underlying undisclosed pato-physiological mechanism is present. The investigatorspropose an international multicenter analysis on the epidemiology and the burden of BAGI in the context of major trauma, exploring differences between BAGI and non-BAGI patients.

Primary endpoint:

  • Relationship between trauma severity (Injury Severity Score) of thoraco-abdominal trauma patients with BAGI versus torso trauma patients without BAGI

Secondary endpoint:

  • Organ Injury Scale of the blunt adrenal trauma(OIS), overall survival, ICU length of stay, overall length of stay

Methods:

Patients will be enrolled according to the reported criteria. The following variables will be considered: - Demographic (age, sex, comorbidities) - Mechanism of trauma - Trauma bay and surgical management - Trauma severity (ISS, NISS, OIS, AIS) - Need for ventilation (Y/N, timing) - Data on vasoactive support - Post trauma clinical and laboratory parameters - Mortality - Length of stay (ICU, hospital) All information of patients will be extracted from our dedicated Trauma Registry and personal informations will be removed according to data anonymization, and collected in an electronic database.

Data will be reported in accordance with Strengthening the Reporting of Observational studies in Epidemiology guidelines (STROBE) for observational studies.

Statistical analysis A 1:1 propensity score matching analysis will be performed based on sex, setting of the trauma, trauma mechanism, age, ASA classification, intentionality of the trauma, Glasgow coma scale and Revised Trauma Score. Following the propensity score matching patients included with and without BAGI will be compared using χ2 test for categorical variables and t-student test or Mann-Whitney test according to sample distribution for continuous variables

02

Conditions studied

  • Trauma
  • Adrenal Gland Injury

Browse trials for

Keywords

  • Trauma
  • blunt adrenal gland trauma
  • major trauma
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients presenting to ED diagnosed with acute appendicitis and eligible for laparoscopic appendectomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 16 years old
  • All patients with blunt thoraco-abdominal trauma

Exclusion criteria

Exclusion criteria:

  • TBI with AIS > 3
  • Isolated TBI and Spinal cord injury
  • Patients died in emergency department
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • BAGI

    patients suffering from thoraco-abdominal blunt trauma with and without blunt adrenal gland injury

06

What researchers measure

Primary outcomes

  1. Injury Severity Score (ISS)

    The Injury Severity Score (ISS) is an established medical score to assess trauma severity.It correlates with mortality, morbidity and hospitalization time after trauma. It is used to define the term major trauma. A major trauma (or polytrauma) is defined as the Injury Severity Score being greater than 15.The AIS Committee of the Association for the Advancement of Automotive Medicine (AAAM) designed and improves upon the scale. Injury Severity Score Minimum: 0 Maximum: 75 The risk of mortality and post trauma complications raises with increasing values in Injury Severity Score.

    Time frame: 120 days after trauma

Secondary outcomes

  1. Presence and number of thoraco-abdominal injuries

    The presence of a specific organ injury per each thoraco-abdominal organ will be registered, defining the presence of an injury as a dichotomous variable (0 absent, 1 present)

    Time frame: 120 days

  2. Organ Injury Scale of the blunt adrenal trauma(OIS)

    The presence of a blunt adrenal gland injury will be registered and classified following the America Association for Surgery of Trauma Organ Injury Scale classification as follow: I Contusion II Laceration involving only cortex (\<2 cm) III Laceration extending into medulla (\> 2 cm) IV \>50% parenchymal destruction V Total parenchymal destruction (including massive intraparenchymal hemorrhage) Avulsion from blood supply

    Time frame: 120 days

  3. Overall survival

    The final outcome of the patient at 120 days will be registered as a dichotomous variable (0 survived, 1 dead)

    Time frame: 120 days

  4. Overall length of stay

    The length of stay in the hospital will be recorded considering it as the time frame, in days, from patient's admission to the emergency department to death or to the discharge to home or a rehabilitation service

    Time frame: 120 days

  5. Overall length of stay at ICU

    The length of stay in the Intensive Care Unit will be recorded considering it as the time frame, in days, from patient's admission in the ICU to death or to the discharge to a surgical or medical ward

    Time frame: 120 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 24, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Sep 30, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Jun 30, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 30, 2026→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06220448
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Jan 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Stefano P Cioffi, MD
Contact
stefanopiero.cioffi@ospedaleniguarda.it
+3386032519
Laura Benuzzi, MD
Contact
laura.benuzzi@unimi.it

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion